The TGF-β Pathway in Hepatocellular Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 31 July 2026 | Viewed by 140
Special Issue Editor
Special Issue Information
Dear Colleagues,
Transforming growth factor-β (TGF-β) plays essential roles in physiological processes, including embryonic development, tissue repair, and immune modulation. During early tumorigenesis, TGF-β acts as a tumor suppressor; in advanced cancers, it promotes tumor invasion and metastasis, angiogenesis, fibroblast activation, and immune evasion. Therefore, TGF-β has emerged as a promising therapeutic target for cancer, with multiple small-molecule inhibitors and antibody drugs currently under clinical development.
In HCC, TGF-β is implicated across all disease stages, from chronic liver injury and liver fibrosis/cirrhosis to carcinogenesis, invasion, and metastasis. This Special Issue aims to provide the most up-to-date knowledge on TGF-β signaling in HCC and the evolving landscape of TGF-β-targeting therapies in HCC. Special emphasis will be placed on translational research leveraging clinical samples and/or clinical trials. Original research articles and reviews are welcome. Topics of interest include, but are not limited to, TGF-β signaling in pathogenesis, diagnosis, prognosis, prevention, and treatment of HCC.
Dr. Dan Feng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- HCC
- TGF-β
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
